NCT06191250View on ClinicalTrials.gov

--SuPERIOR Trial--

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 28, 2024

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Non-Small Cell Lung Cancer (NSCLC)Clinical Staging T2b-3 N0-1 M0
Interventions
DRUG

Durvalumab

one dose of durvalumab (750 mg IV)

RADIATION

Non-ablative oligofractionated radiation (NORT)

12 Gy of Radiation in 3 fractions

Trial Locations (1)

Unknown

University Health Network, Toronto

Sponsors
All Listed Sponsors
collaborator

Ontario Institute for Cancer Research

OTHER

lead

University Health Network, Toronto

OTHER